

DEVELOPMENTAL RESEARCH PROJECTS - IMMUNOTOXICITY Request for Applications

Purpose: The DLDCCC is interested in providing pilot support to innovative translational research projects that may evolve into full grants or SPORE projects or that may secure other peer-reviewed funding. The projects must focus on **toxicities of immune therapies (e.g. cell therapy transplant or checkpoint inhibition) and/or pathologic inflammation associated with cancer**. With this RFA, we are also expanding the application to include fundamental immunology that may be relevant to broader immune pathology mechanisms.

Funding: The DLDCCC will fund up to 3 projects for one-year each with budgets up to \$50,000.

Structure: The application will follow the format of an NIH research grant application but will be limited to 3 pages. We request that interested investigators contact Dr. Carl Allen if they are unsure whether their proposal would fit this RFA.

Review: The DLDCCC will utilize a standing review committee to consider applications according to standard NIH criteria (significance, approach, etc.).

Applications: Please use (apart from the cover sheet) NIH PHS 398 forms which can be obtained at the following web site. <https://grants.nih.gov/grants/funding/phs398/phs398.html>. Awarded projects will be expected to spend the funds within 1 year with a possible extension depending on progress/justification. Programs should be gearing toward submitting an external grant application within 12-18 months of the pilot award.

Submission: Applications should be submitted through the [DLDCCC Proposal Submission Portal](#) by March 31, 2025, and include:

- 1) Cover sheet with Project title and Investigators. Please include affiliation of investigators.
- 2) Form Page 2: Description, Performance Sites, Key Personnel, Other Significant Contributors and Abstract.
- 3) Form Page 4: Detailed Budget for Initial Budget Period
- 4) Biographical Sketches for key personnel
- 5) Research Plan on continuation pages. This section is limited to a total of 3 pages (not including references) and should include:
 - a) Specific Aims – 1 page
 - b) Research Strategy organized to address review criteria (Significance, Innovation, Approach) – 2 pages
- 6) If your application uses clinical material, please provide your IRB approval letter.

Questions about this RFA to Carl Allen ceallen@txch.org.